Human Genome Sciences plans to release late-stage clinical data on Benlysta, its experimental drug for lupus, on Monday, reports Dow Jones Newswires. The story adds that lupus is "a notoriously hard-to-treat autoimmune disease that hasn't seen a new therapy in decades." Human Genome Sciences partnered with GlaxoSmithKline and worked closely with FDA to design its phase III trial after the phase II trial failed. The article says that if this first trial fails — Barclays analyst Jim Birchenough estimates an 85 percent chance of failure — the company's stock will likely drop to about $1; but if it meets its endpoints, the stock could reach higher than $10.
Crossing Their Fingers
Jul 16, 2009